Annexon, Inc (ANNX) Stock Forecast & Price Target

Annexon is viewed favorably because its C1q-targeted platform attacks the earliest step in the classical complement cascade, offering a differentiated mechanism that may preserve vision and reduce neuroinflammation while avoiding some safety and convenience drawbacks of existing GA therapies. The bull case is strengthened by vonaprument’s Phase 2 signals of vision preservation, the large underserved GA market where Syfovre and Izervay generated about $1.1B in 2025 sales, and additional upside from tanruprubart in GBS plus ANX1502’s oral complement-inhibition potential. Financially, the company had $225M in cash at 1Q26, providing runway into 2H27, while the recent credit facility extends runway into 2028 and supports key readouts including ARCHER II in 4Q26 and 3Q27.

Annexon is fundamentally challenged by a weak clinical read-through on its lead ophthalmology asset, because vonaprument missed the Phase 2 ARCHER primary endpoint and its modest 6.2% lesion-growth reduction trails approved GA therapies that cut lesion growth by roughly 17% to 35%. The apparent vision-preservation signal is still unproven in a larger, enriched Phase 3 setting, where BCVA noise, structural-function dissociation in GA, and the company’s own need for a much lower event rate all raise the odds of another miss. Financially, 2Q26 OpEx was $57M, net loss was $53M, cash was $209M, and despite a $50M draw on the new credit facility the business is expected to keep burning cash and may need dilutive capital before commercialization.